Selvita participates in BioTrinity 2018

Kraków, Poland – 23 April 2018 – Selvita will participate in the 2018 edition of BioTrinity conference, taking place in London, UK, on April 23 – 25, 2018. BioTrinity is one of Europe’s leading biopartnering and investment conferences, and the largest of its type in the UK. The conference offers…

More

Selvita publishes research results on SEL24 in Oncotarget

Krakow, Poland – 16 April 2018 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, has published recent results of a research concerning therapeutic potential of SEL24 in Acute Myeloid Leukemia (AML). The article titled “A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits…

More

Selvita shows a very strong, 60% business growth in 2017

Krakow, Poland – 04 April 2018 – Selvita, one of the largest drug discovery companies in Europe, has recently published annual financial results demonstrating its strong and dynamic business performance across all segments. Throughout 2017, Selvita Group recognized revenues from operating activities in the amount of PLN 105.9 MM –…

More

Selvita Announces Successful Completion of $41 M Book Building

*** NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN *** Krakow, Poland – 16 February 2018 – Selvita (WSE:SLV), one of the largest drug discovery companies in Europe, has received investment declarations implicating placement of all 2,200,000 shares offered in the H series public subscription. The issue…

More

Selvita Appoints Steffen Heeger, M.D., PhD as Chief Medical Officer

Kraków, Poland – 06 February 2018 – Selvita S.A. (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer. Dr. Heeger will join Selvita…

More

12345...10...